Streptococcus pneumoniae is the most common causative pathogen in community-acquired pneumonia. Protease-activated receptor 2 (PAR2) is expressed by different cell types in the lungs and can mediate inflammatory responses. We sought to determine the role of PAR2 during pneumococcal pneumonia. Pneumococcal pneumonia or sepsis was induced in wild-type and PAR2 knock-out (Par2−/−) mice by infection with viable S. pneumoniae. Par2−/− mice demonstrated improved host defense, a largely preserved lung barrier integrity, and reduced mortality during pneumococcal pneumonia. PAR2 deficiency did not influence bacterial growth after intravenous infection. Inhibition of the endogenous PAR2 activating proteases tissue factor/factor VIIa or tryptase did not impact on bacterial burdens during pneumonia. In a PAR2 reporter cell line it was demonstrated that S. pneumoniae-derived proteases are able to cleave PAR2. These results show that S. pneumoniae is able to cleave and exploit PAR2 to disseminate systemically from the airways.
Community-acquired pneumonia (CAP) is a common illness throughout the world, with an estimated incidence of 1-2 million in the USA [1, 2] . Streptococcus pneumoniae is the main causative pathogen for CAP, accounting for up to 60% of bacterial cases. Mortality rates have stagnated over the past decades and with an emerging increase in resistant serotypes [1] alternative measures are indispensable to expand current treatment options.
During lung infection many mediators interact to mount an inflammatory response to protect the host from invading pathogens. Protease-activated receptors (PARs) have been shown to play a key role in the regulation of inflammation in the lungs [3] . These unique seven transmembrane G-protein coupled receptors bear their own ligand, which becomes exposed after proteolytic cleavage of their extracellular amino-terminal domain [3] . Four PARs have been identified, each of which can be activated by a variety of proteases. PAR1, 3, and 4 have in common that they can be activated by thrombin. PAR2 is relatively resistant to thrombin but can be readily activated by host endogenous proteases such as trypsin, tryptase, granzyme A, and the coagulation proteases factor (F) VIIa and Xa, as well as by a number of bacteria-derived enzymes [4] . Conversely, PAR2 can be disarmed by proteinase-3, cathepsin G [4] , and (Pseudomonas aeruginosa derived) elastase [5] .
PAR2 is widely expressed in lung tissue by epithelial cells, endothelial cells, fibroblasts, and airway and vascular smooth muscle cells [6, 7] but also by nonparenchymal cells like alveolar macrophages and neutrophils [8, 9] . Thus far, the role of PAR2 in lung infection has been reported in 3 studies [10] [11] [12] . PAR2 knockout (Par2−/−) mice were more susceptible to influenza A infection as reflected by enhanced mortality and increased lung pathology [10] ; in 2 bacterial pneumonia models using Escherichia coli [12] or P. aeruginosa [11] Par2−/− mice demonstrated a similar response, and a diminished capacity to clear the bacteria from the airways respectively compared to wildtype (WT) mice. These 2 latter investigations [11, 12] made use of pathogens that are cleared from the lungs of immune-competent animals [13] , which is in accordance with the fact that these gram-negative bacteria almost exclusively cause pneumonia in immune-compromised and/or hospitalized patients [14] .
Here we aimed to determine the role of PAR2 in the course of gram-positive pneumonia caused by S. pneumoniae. To this end, we used our well-established model of CAP, in which Par2−/− and WT mice were instilled with S. pneumoniae via the airways, resulting in a gradually growing bacterial load at the primary site of infection and subsequent dissemination to distant body sites. We show that S. pneumoniae is able to cleave and exploit PAR2 for its growth and systemic dissemination, leading to a worse survival.
MATERIALS AND METHODS

Ethics Statement
Experiments were carried out in accordance with the Dutch Experiment on Animals Act and approved by the Animal Care and Use Committee of the University of Amsterdam (Permit number DIX 100121, subprotocols DIX 101235, DIX 101955, DIX 102092, and DIX 102267).
Mice
Specific pathogen-free C57BL/6 WT mice were purchased from Charles River (Maastricht, The Netherlands). Par2−/− mice on a C57BL/6 genetic background were originally provided by Jackson Laboratories (Bar Harbor, Maine) and bred at the animal care facility of the Academic Medical Centre. All experiments were conducted with 10 to 12-week old gender-matched mice.
Experimental Study Design
S. pneumoniae serotype 3 (American Type Culture Collection, ATCC 6303, Rockville, MD) was used to induce pneumococcal pneumonia and sepsis as described previously [15] [16] [17] ; for induction of pneumonia, 5 × 10 4 colony-forming units (CFU) in 50 µL were inoculated intranasally; for induction of sepsis, 5 × 10 5 CFU in 200 µL were inoculated intravenously. In separate experiments WT and Par2−/− mice were treated subcutaneously with recombinant anticoagulant protein (rNAPc2 [18, 19] ; 10 mg/kg) or vehicle every 6 hours after induction of S. pneumoniae pneumonia; or with the tryptase inhibitor nafamostat mesilate (10 or 30 mg kg −1 ) [20, 21] or vehicle, at time of induction of pneumonia and at 24 hours postinfection. At predefined time points (6, 24, or 48 hours after infection) blood diluted 1:4 with citrate, bronchoalveolar lavage fluid (BALF), lungs, and spleen were harvested. Total cell numbers in BALF were determined by an automated cell counter (Coulter Counter, Coulter Electronics, Hialeah, FL). Differential cell counts were performed on cytospin preparations stained with a modified Giemsa stain (Diff-Quick; Dade Behring AG, Düdingen, Switzerland). The left lung lobe was fixed in 10% buffered formalin and embedded in paraffin. The remaining lung lobes and a part of the spleen were harvested and homogenized.
Bacterial Quantification
To assess bacterial loads, undiluted whole blood and serial 10-fold dilutions of organ homogenates, BALF, and whole blood were made in sterile isotonic saline and plated onto sheep-blood agar plates. CFUs were counted following 16 hours of incubation at 37°C.
Lung Permeability Assay
Evans blue dye (100 μL of 5 mg/mL) was injected in the tail vein 90 minutes before the mouse was sacrificed 20 or 42 hours after infection with S. pneumoniae. Lungs were flushed with 10 mL of phosphate buffered saline (PBS) to wash out all remaining blood, after which the right lung was photographed using a Canon Powershot digital camera. Next, the lungs were blotted dry, weighed, and homogenized in PBS (1 mL/100 μg tissue), after which 2 volumes of formamide were added. After 18 hours of incubation at 60°C, samples were centrifuged at 12 000 × g for 20 minutes, and optical densities of the supernatants were determined by spectrophotometry at 620 nm and 740 nm in 96-well plates using a BioTek Synergy HT Multi-Mode Microplate Reader. Evans blue dye concentrations were calculated using the lung-specific correction factor, as described previously [22] .
Histopathology
Four-micrometre sections of the left lung lobe were stained with hematoxylin and eosin (H&E). All slides were coded and scored by a pathologist who was blinded for group identity, as described previously [15] . Neutrophil staining was performed using an anti-mouse Ly-6G monoclonal antibody (BD Pharmingen, San Diego, CA), as described previously [15, 23] .
Assays
Commercially available enzyme-linked immunosorbent assays (ELISAs) were used to measure myeloperoxidase (MPO; Hycult, Uden, the Netherlands), macrophage-inflammatory protein (MIP)-2, keratinocyte-derived cytokine (KC), lipopolysaccharide-induced CXC chemokine (LIX), interleukin (IL)-1β (all R&D Systems, Abingdon, UK), and thrombin-antithrombin complexes (TATc; Affinity Biologicals, Ancaster, Ontario, Canada). Tumor necrosis factor alpha (TNF-α) and IL-6 were determined using a commercially available cytometric beads array multiplex assay (BD Biosciences, San Jose, CA). Total protein in BALF was determined using a Bradford protein assay kit (Bio-Rad laboratories, Hercules, CA).
Tryptase Activity Assay
To determine tryptase activity in BALF, an assay was performed as previously described [24] . In brief, BALF was incubated with the chromogenic substrate S-2288 (H-D-Ile-Pro-Arg p-nitroanilide; Chromogenix-Instrumentation Laboratory SpA, Milan, Italy) at 37°C. Immediately after addition of BALF, p-nitroaniline release from S-2288 was monitored at 405 nm. Tryptase activity was represented as the difference from optical density at zero time.
S. pneumoniae Lysate
S. pneumoniae were cultured in THY medium, then washed with sterile saline 3 times. The bacterial pellet was diluted to a concentration of 1 × 10 9 CFU/mL. The bacteria were subsequently lysed in 5 freeze-thaw cycles (liquid nitrogen and 37°C water bath) and stored at −20°C before use.
PAR2 Cleavage Reporter Assay
Generation of HEK293 PAR2 SEAP reporter cells has been described before [25] . In brief, these HEK293 cells express PAR2 to which an alkaline phosphatase (AP) is attached to its N-terminus. Proteolytic cleavage of the receptor leads to the release of AP into the medium, which is subsequently measured using an AP substrate kit (#T1015, Life Technologies, Toronto, Canada). For the assay, 100 000 cells/well were seeded in Minimum Essential Medium (#21090, ThermoFisher Scientific, Whaltham, MA), supplemented with 10% fetal calf serum (FCS), l-glutamine, and antibiotics, in a 96-well plate. The next day, the cells were stimulated with 60 µL S. pneumoniae lysate (equivalent to 1 × 10 7 CFU) or solvent control (normal growth medium) for 150 minutes. Next, the supernatant was removed and centrifuged at 12 000g for 3 minutes to remove cellular debris. Luminescence was determined using a Biotek Synergy HT (Biotek, Winooski, VT).
Statistical Analysis
Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile, and largest observation, or as Kaplan-Meier plots. Differences between groups were analyzed by t test, Mann-Whitney U, or Kruskal-Wallis test when appropriate. Survival curves were compared using log-rank test. Differences in bacteremia were analyzed by Fisher's exact test. A P value of <.05 was considered statistically significant.
RESULTS
The Presence of PAR2 Impairs Survival During S. pneumoniae Pneumonia
To obtain a first insight into the role of PAR2 in the outcome of pneumococcal pneumonia, Par2−/− and WT mice were infected intranasally with viable S. pneumoniae and observed for 10 days. Par2−/− mice were significantly protected from mortality; lethality amongst WT mice was 100% within 6 days, whereas 47% of Par2−/− mice survived ( Figure 1 , P = .007).
Dissemination of S. pneumoniae is Facilitated in the Presence of PAR2
To obtain insight into the mechanism by which Par2−/− mice were protected against lethality we quantified bacterial loads in BALF, lung homogenates, and blood and spleen homogenates at predefined time points after infection. Bacterial numbers in BALF and lung homogenates of Par2−/− mice were significantly reduced at 24 (BALF only) and 48 hours (Figure 2A and B). Lower bacterial counts in lungs of Par2−/− mice were accompanied by diminished dissemination of bacteria as reflected by a reduction in the number of positive blood cultures (P = .08 at 48 hours, Fisher's exact test) and reduced bacterial loads in their spleen ( Figure 2C and D).
PAR2 Plays a Limited Role in the Inflammatory Response to
Pneumococcal Pneumonia PAR2 can mediate a variety of inflammatory effects in the airways [7] . We evaluated the number and type of cells in BALF harvested from Par2−/− and WT mice (Table 1) . At 24 hours, Par2−/− mice transiently demonstrated lower total neutrophil counts in BALF. Notably, MPO levels measured in whole lung homogenates as a measure of total neutrophil content were not different between groups at any time point (Table 1) . In accordance, the number of Ly6G + cells (neutrophils) in lung tissue slides did not differ between Par2−/− and WT mice (Supplementary Figure S1) . Furthermore, the concentrations of the neutrophil-attracting CXC chemokines LIX, KC, and MIP-2 measured in BALF and lung homogenates were not different between groups at any time point (Table 1) . Lung cytokine levels were modestly reduced in Par2−/− mice relative to WT mice at 24 hours postinfection (Table 1 ). In accordance, the extent of lung pathology did not differ between Par2−/− and WT mice (Supplementary Figure S2) .
PAR2 Impairs Lung Barrier Integrity
To establish whether PAR2 favors the replication of S. pneumoniae in the systemic compartment, we examined bacterial loads after direct intravenous injection of S. pneumoniae, thereby by-passing the effect of PAR2 in the airways. In these studies no differences in CFU counts in whole blood, spleen, liver, or lung homogenates were found between WT and Par2−/− mice (Supplementary Figure S3) . Bacteria may cross the lung-blood barrier by directly inducing alveolar epithelial cell injury [26] . We evaluated S. pneumoniae-induced Evans blue dye leakage 20 and 42 hours after infection. At both time points, WT mice had increased bacterial loads in the lung ( Figure 3A) . At 20 hours, none of the mice showed bacteremia; however, at 42 hours WT mice again showed increased bacterial loads in blood with significantly more bacteremia (P = .0014, Fisher's exact test) compared to Par2−/− mice ( Figure 3B ). S. pneumoniae increased blood-lung barrier permeability, as reflected by Evans blue levels that were significantly higher compared to uninfected WT mice ( Figure 3C ), confirming previous results [22] . Importantly, Evans blue leakage was strongly reduced in Par2−/− mice ( Figure 3C , D), suggesting that PAR2 impedes lung barrier protection during airway infection by S. pneumoniae. BALF protein levels were not different between 6, 24, or 48 hours after infection and there were no differences between Par2−/− and WT mice (Supplementary Figure S4) , suggesting that measurements of total protein in BALF were not as sensitive as the Evans blue method to detect impaired barrier integrity.
TF/FVIIa/FXa Inhibitor rNAPc2 Attenuates Coagulation but Does not Affect
Bacterial Loads in Par2−/− or WT Mice PAR2 can be activated by coagulation proteases factor (F)VIIa and Xa [27] . To study the role of FVIIa and FXa in the activation of PAR2 during pneumococcal pneumonia we treated Par2−/− and WT mice with rNAPc2, a small protein that inhibits tissue factor (TF)/FVIIa mediated coagulation [19] . Elevated thrombin-antithrombin complex (TATc) concentrations, in lung homogenates and plasma of infected WT mice were strongly reduced by rNAPc2, confirming previous results [19] We previously reported that mast cell-deficient mice show a reduced bacterial growth and dissemination in this model of pneumococcal pneumonia, resembling the phenotype of Par2−/− mice in the current study [28] . Tryptase is a main product released by mast cells, and a potent activator of PAR2 Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile, and largest observation (n = 8 per group). ***P < .001, **P < .01 compared to infected WT mice, ## P < .01 compared to uninfected WT mice. [3, 29] . Therefore, we sought to study the potential role of tryptase in PAR2 activation [21, 30] during pneumococcal pneumonia. In BALF obtained from WT mice 6 and 48 hours postinfection, tryptase activity remained undetectable (data not shown). Moreover, treatment of mice with the tryptase inhibitor nafamostat [31] during pneumococcal pneumonia did not influence bacterial burdens in BALF, lungs, blood, or spleen ( Figure 5 ).
S. pneumoniae-Derived Proteases Cleave PAR2
As we were not able to demonstrate that the candidate endogenous proteases play a crucial role in PAR2-mediated host defense during pneumococcal pneumonia, we next sought to investigate a potential role for pneumococcal derived proteases in an interaction with PAR2. In order to determine whether proteases expressed by S. pneumoniae are able to cleave PAR2, PAR2 reporter cells [25] were stimulated with S. pneumoniae . Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile, and largest observation (n = 7-8 per group). ***P < .001, **P < .01, *P < .05. #P < . 10. lysate. As shown in Figure 6 , S. pneumoniae stimulation led to an approximate 4.5-fold induction of AP release into the medium showing that S. pneumoniae proteases are able to cleave PAR2.
DISCUSSION
PAR2 can be activated by proteases released from host cells or pathogens during inflammatory and infectious conditions. Pulmonary PAR2 activation can have both host protective and detrimental effects depending on the type of the inflammatory assault [7] . We here evaluated the role of PAR2 in an established clinically relevant CAP model characterized by gradual growth of S. pneumoniae at the primary site of infection followed by dissemination. We demonstrated that the presence of PAR2 led to an increased mortality, most likely as a consequence of enhanced bacterial pulmonary loads and impairment of the lung-blood barrier integrity with subsequent higher rates of systemic dissemination. Preventing activation by several endogenous proteases of PAR2 did not affect bacterial growth or dissemination. Instead, we show that proteases derived from S. pneumoniae are capable of PAR2 cleavage, providing a mechanism by which S. pneumoniae is able to exploit PAR2 to disseminate from the airways.
Both protective and deleterious PAR2-mediated effects have been demonstrated, varying with different intruding pathogens and sites of infection [4] . In lung infection by influenza A, PAR2 dampened neutrophil migration to lung alveoli and protected mice from lung injury and lethality [10] . In pneumonia caused by P. aeruginosa, PAR2 enhanced bacterial clearance from the airways [11] , whereas no apparent role of PAR2 was found in the pathogenesis of acute E. coli airway infection [12] . In contrast to these reports, in the present study we describe for the first time a detrimental role for PAR2 in lung infection. PAR2-deficient mice were strongly protected during pneumococcal pneumonia in 4 separate experiments, with lower numbers of bacteria in organs, and bacteremia in only about half of infected Par2−/− mice. Bacterial numbers in positive blood cultures were not different between WT and Par2−/− mice during pneumococcal pneumonia or sepsis, indicating that the relative protection of Par2−/− mice resided in the pulmonary compartment. Bacterial burdens did not differ between mouse strains early after infection and the survival difference between Par2−/− and WT mice only became evident >2 days after infection. From these observations we propose that the bacterial load needs to exceed a certain threshold before the effect of these bacteria on PAR2 becomes biologically relevant and facilitates systemic dissemination over the lung epithelial-endothelial barrier. Both in vitro and in vivo data support this theory; in primary respiratory epithelial cells PAR2 compromised the integrity of respiratory epithelium [32] and a PAR2 activating peptide instilled into airways increased airway endothelial and epithelial permeability to protein in mice [33] . In accordance, we here show that PAR2 impairs the blood-lung barrier during pneumococcal pneumonia using the Evans blue dye assay. Furthermore, Par2−/− mice had reduced bacterial numbers in the lungs when compared with WT mice. This suggests that PAR2 plays an additional role in impairing host defense at the primary site of infection; however, our study is limited in that it does not provide insight into the mechanisms involved herein. The role of PAR2 in the induction of lung inflammation varies depending on the inciting stimulus [3, 4] . In acute pneumonia caused by P. aeruginosa, Par2−/− mice displayed enhanced neutrophil influx into BALF and elevated BALF TNF-α levels, possibly induced by higher bacterial loads [11] . Likewise, Par2−/− mice demonstrated increased neutrophil recruitment in BALF during influenza A infection coinciding with strongly elevated viral titers in their lungs [10] . We here found little if any effect of PAR2 on the proinflammatory response to S. pneumoniae in the lungs, as reflected by similar neutrophil counts in lung tissue, lung histopathology, and pulmonary cytokine and chemokine levels in Par2−/− and WT mice. Together these data argue against the possibility that Par2−/− mice are protected during pneumococcal pneumonia by a mechanism in which the lack of PAR2 improves an adequate proinflammatory immune response required for limiting bacterial multiplication.
During pneumonia a rise in levels of TF initiates coagulation via the recruitment of FVIIa and Xa [34] , which can activate PAR2 [27] . Inhibiting FVIIa and/or FXa with rNAPc2 significantly reduced coagulation in both WT and Par2−/− mice, but did not reduce bacterial numbers, confirming previous results obtained with this inhibitor [19] and recombinant TF pathway inhibitor [15] . rNAPc2 treatment was associated with an increase in bacterial loads in spleens of WT and Par2−/− mice, suggesting that local coagulation may help to compartmentalize infection. Together these data argue against a role of FVIIa and/ or FXa in PAR2 activation during pneumococcal pneumonia. Of note, Par2−/− mice demonstrated diminished coagulation activation in their lungs compared to WT mice at 48 hours after infection, possibly caused by the lower pulmonary bacterial burdens in Par2−/− mice, providing a less-potent procoagulant stimulus. Similarly, in a model of lung fibrosis, Par2−/− mice displayed less TF expression and fibrin generation, possibly due to attenuated inflammation [35] .
Among immune cells that are recruited to the site of infection are mast cells that are able to release tryptase [4] . In vitro, mast cell tryptase impairs endothelial barrier function through activation of endothelial PAR2 [21] . In addition, mast cell-deficient mice demonstrated a similarly improved host defense in this model as observed here in Par2−/− mice [28] . However, we could not detect any tryptase activity in BALF samples of infected mice and inhibiting tryptase activity with nafamostat did not impact on bacterial growth or dissemination, arguing against a role for tryptase in PAR2-mediated impaired host defense during pneumococcal pneumonia.
Respiratory pathogens are a source of many proteases that have the potency to interact with PAR2 [3] . S. pneumoniae expresses proteases [36] , but to date it has been unknown whether these proteases have PAR2 cleaving properties. We here show that incubation of lysate containing proteases expressed by S. pneumoniae with PAR2 reporter cells results in cleavage of the receptor. Although an interaction between S. pneumoniae and PAR2 provides a potential mechanism by which S. pneumoniae facilitates its own dissemination, a crucial role for this interaction during pneumococcal pneumonia still requires confirmation in vivo.
In conclusion, in our experimental model of CAP we found that the presence of PAR2 leads to enhanced growth and dissemination of S. pneumoniae, at least in part by impairing the integrity of the lung-blood barrier, ultimately resulting in a worsened survival. This study is the first to document that a common respiratory pathogen profits from the presence of PAR2 and that it possesses PAR2 cleaving properties. These results imply that S. pneumoniae may benefit from a direct proteolytic interaction with PAR2 to cause invasive infection.
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